These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 25505248)

  • 21. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
    Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
    Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism.
    Spires TL; Grote HE; Varshney NK; Cordery PM; van Dellen A; Blakemore C; Hannan AJ
    J Neurosci; 2004 Mar; 24(9):2270-6. PubMed ID: 14999077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in huntington disease drug discovery: novel approaches to model disease phenotypes.
    Bard J; Wall MD; Lazari O; Arjomand J; Munoz-Sanjuan I
    J Biomol Screen; 2014 Feb; 19(2):191-204. PubMed ID: 24196395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive Dysfunction in Huntington's Disease: Humans, Mouse Models and Molecular Mechanisms.
    Giralt A; Saavedra A; Alberch J; Pérez-Navarro E
    J Huntingtons Dis; 2012; 1(2):155-73. PubMed ID: 25063329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Morphological control of mitochondria as the novel mechanism of Gastrodia elata in attenuating mutant huntingtin-induced protein aggregations.
    Huang NK; Lin CC; Lin YL; Huang CL; Chiou CT; Lee YC; Lee SY; Huang HT; Yang YC
    Phytomedicine; 2019 Jun; 59():152756. PubMed ID: 31004885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice.
    Wong BKY; Ehrnhoefer DE; Graham RK; Martin DDO; Ladha S; Uribe V; Stanek LM; Franciosi S; Qiu X; Deng Y; Kovalik V; Zhang W; Pouladi MA; Shihabuddin LS; Hayden MR
    Neurobiol Dis; 2015 Apr; 76():24-36. PubMed ID: 25583186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Possible role of mitochondrial permeability transition pore in the pathogenesis of Huntington disease.
    Quintanilla RA; Tapia C; Pérez MJ
    Biochem Biophys Res Commun; 2017 Feb; 483(4):1078-1083. PubMed ID: 27638306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Partial depletion of CREB-binding protein reduces life expectancy in a mouse model of Huntington disease.
    Klevytska AM; Tebbenkamp AT; Savonenko AV; Borchelt DR
    J Neuropathol Exp Neurol; 2010 Apr; 69(4):396-404. PubMed ID: 20448484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brain-Derived Neurotrophic Factor Prevents Depressive-Like Behaviors in Early-Symptomatic YAC128 Huntington's Disease Mice.
    da Fonsêca VS; da Silva Colla AR; de Paula Nascimento-Castro C; Plácido E; Rosa JM; Farina M; Gil-Mohapel J; Rodrigues ALS; Brocardo PS
    Mol Neurobiol; 2018 Sep; 55(9):7201-7215. PubMed ID: 29388082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early Downregulation of p75
    Suelves N; Miguez A; López-Benito S; Barriga GG; Giralt A; Alvarez-Periel E; Arévalo JC; Alberch J; Ginés S; Brito V
    Mol Neurobiol; 2019 Feb; 56(2):935-953. PubMed ID: 29804232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
    Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.
    Apostol BL; Simmons DA; Zuccato C; Illes K; Pallos J; Casale M; Conforti P; Ramos C; Roarke M; Kathuria S; Cattaneo E; Marsh JL; Thompson LM
    Mol Cell Neurosci; 2008 Sep; 39(1):8-20. PubMed ID: 18602275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.
    Kusko R; Dreymann J; Ross J; Cha Y; Escalante-Chong R; Garcia-Miralles M; Tan LJ; Burczynski ME; Zeskind B; Laifenfeld D; Pouladi M; Geva M; Grossman I; Hayden MR
    Mol Neurodegener; 2018 May; 13(1):25. PubMed ID: 29783994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Site-specific ubiquitination of pathogenic huntingtin attenuates its deleterious effects.
    Hakim-Eshed V; Boulos A; Cohen-Rosenzweig C; Yu-Taeger L; Ziv T; Kwon YT; Riess O; Phuc Nguyen HH; Ziv NE; Ciechanover A
    Proc Natl Acad Sci U S A; 2020 Aug; 117(31):18661-18669. PubMed ID: 32675242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
    Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
    Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lycium barbarum polysaccharide attenuates the cytotoxicity of mutant huntingtin and increases the activity of AKT.
    Fang F; Peng T; Yang S; Wang W; Zhang Y; Li H
    Int J Dev Neurosci; 2016 Aug; 52():66-74. PubMed ID: 27196502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease.
    Caron NS; Southwell AL; Brouwers CC; Cengio LD; Xie Y; Black HF; Anderson LM; Ko S; Zhu X; van Deventer SJ; Evers MM; Konstantinova P; Hayden MR
    Nucleic Acids Res; 2020 Jan; 48(1):36-54. PubMed ID: 31745548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous immunoglobulin ameliorates motor and cognitive deficits and neuropathology in R6/2 mouse model of Huntington's disease by decreasing mutant huntingtin protein level and normalizing NF-κB signaling pathway.
    Liu SY; Yu XL; Zhu J; Liu XM; Zhang Y; Dong QX; Ma S; Liu RT
    Brain Res; 2018 Oct; 1697():21-33. PubMed ID: 29902468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ESC-Derived BDNF-Overexpressing Neural Progenitors Differentially Promote Recovery in Huntington's Disease Models by Enhanced Striatal Differentiation.
    Zimmermann T; Remmers F; Lutz B; Leschik J
    Stem Cell Reports; 2016 Oct; 7(4):693-706. PubMed ID: 27693427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement of BDNF signalling by P42 peptide in Huntington's disease.
    Couly S; Paucard A; Bonneaud N; Maurice T; Benigno L; Jourdan C; Cohen-Solal C; Vignes M; Maschat F
    Hum Mol Genet; 2018 Sep; 27(17):3012-3028. PubMed ID: 29860423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.